Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 10/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19323689 | 0.93 | KDM4E (0.50) | KDM4EALDH1A1GAARXFP1APOBEC3G | |
| SCHEMBL14985644 | 0.86 | — | — | |
| SCHEMBL7203426 | 0.74 | ALDH1A1 (0.50) | KDM4EALDH1A1GAARXFP1APOBEC3G | |
| SCHEMBL18190439 | 0.70 | ALDH1A1 (0.43) | KDM4EALDH1A1GAARXFP1APOBEC3G | |
| SCHEMBL13925998 | 0.69 | HAVCR2 (0.45) | KDM4EALDH1A1GAARXFP1APOBEC3G | |
| SCHEMBL10533578 | 0.65 | KDM4E (0.33) | KDM4EHAVCR2 | |
| SCHEMBL17349118 | 0.64 | SMN1; SMN2 (0.43) | KDM4EALDH1A1GAARXFP1APOBEC3G | |
| SCHEMBL18020322 | 0.64 | SMN1; SMN2 (0.32) | ALDH1A1GAARXFP1APOBEC3GSMN1; SMN2 | |
| SCHEMBL22814677 | 0.63 | HAVCR2 (0.40) | KDM4EALDH1A1HAVCR2MAPTLMNA | |
| SCHEMBL11593915 | 0.62 | SMN1; SMN2 (0.62) | KDM4EALDH1A1HAVCR2MAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD. (CN) | 2017-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170253614-A1 | HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS | HAVCR2, HCCS, LIPC | KDM4E 3963/4885ALDH1A1 1148/4885GAA 214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.